Dalia Barsyte-Lovejoy
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Year:
2026
Year:
2025
Year:
2024
Sperm activation is controlled by an influx of calcium ions through the CatSper channel, which is activated in the oviduct by a non-genomic action of progesterone. Progesterone has been hypothesized to act as an activator of ABHD2 activity, which in turn hydrolyses 1- and 2- arachadinoyl glycerol, putative inhibitors of CatSper. To explore the idea of targeting ABHD2 activity as a contraceptive target, we synthesized derivatives of published ABHD2 inhibitors, optimizing for potency and in-cell target engagement, and tested active inhibitors and structurally-related inactive derivatives in sperm motility assays and calcium influx assays. We observed no effect of ABHD2 inhibition on basal or progesterone-induced activity in both assays. We also found no evidence for direct binding of progesterone to purified recombinant ABHD2 protein. We conclude that ABHD2 activity is not required for the non-genomic action of progesterone on human sperm.
Year:
2024
A promising drug target, SETDB1, is a dual Kme reader and methyltransferase, which has been implicated in cancer and neurodegenerative disease progression. To help understand the role of the triple Tudor domain (3TD) of SETDB1, its Kme reader, we first identified a low micromolar small molecule ligand, UNC6535, which occupies simultaneously both the TD2 and TD3 reader binding sites. Further optimization led to the discovery of UNC10013, the first covalent 3TD ligand targeting Cys385 of SETDB1. UNC10013 is potent with a k inact /K I of 1.0 x 10 6 M -1 s -1 and demonstrated proteome-wide selectivity. In cells, negative allosteric modulation of SETDB1-mediated Akt methylation was observed after treatment with UNC10013. Therefore, UNC10013 is a potent, selective and cell-active covalent ligand for the 3TD of SETDB1, demonstrating negative allosteric modulator properties and making it a promising tool to study the biological role of SETDB1 in disease progression.
Year:
2024
A promising drug target, SETDB1, is a dual Kme reader and methyltransferase, which has been implicated in cancer and neurodegenerative disease progression. To help understand the role of the triple Tudor domain (3TD) of SETDB1, its Kme reader, we first identified a low micromolar small molecule ligand, UNC6535, which occupies simultaneously both the TD2 and TD3 reader binding sites. Further optimization led to the discovery of UNC10013, the first covalent 3TD ligand targeting Cys385 of SETDB1. UNC10013 is potent with a kinact/KI of 1.0 x 106 M-1s-1 and demonstrated proteome-wide selectivity. In cells, negative allosteric modulation of SETDB1-mediated Akt methylation was observed after treatment with UNC10013. Therefore, UNC10013 is a potent, selective and cell-active covalent ligand for the 3TD of SETDB1, demonstrating negative allosteric modulator properties and making it a promising tool to study the biological role of SETDB1 in disease progression.
Year:
2024
Proteolysis-targeting chimeras (PROTACs) have been explored for the degradation of drug targets, particularly undruggable proteins, for more than two decades. They have been employed by various groups successfully, however only a handful of E3 ligase substrate receptors such as CRBN, VHL, MDM2, and IAP have been efficiently used. Downregulation and mutation of these receptors would reduce the effectiveness of PROTACs, thus necessitating the addition of new substrate receptors and E3 ligases to the repertoire to avoid resistance. We recently developed potent ligands for DCAF1, a substrate receptor of EDVP and CUL4 E3 ligases with diverse substrate specificity. Here, we focused on DCAF1 toward the development of PROTACs for WDR5, a drug target in various cancers. We report three DCAF1-based PROTACs with endogenous and exogenous WDR5 degradation effects and solved the first high-resolution crystal structures of DCAF1-PROTAC-WDR5 ternary complexes. The structures reveal detailed insights into the interaction of DCAF1 with various WDR5-PROTACs, including the finding that PROTACs can compress like a spring to similar effective lengths to keep DCAF1 and WDR5 within interaction distance of each other. Furthermore, specific DCAF1 loops play a significant role in providing surface plasticity needed to interact with different PROTAC-WDR5 complexes, reflecting the mechanism by which DCAF1 functions as a substrate receptor for E3 ligases with diverse sets of substrates.
Year:
2024
Damaged DNA-binding protein-1 (DDB1)- and CUL4-associated factor 12 (DCAF12) serves as the substrate recognition component within the Cullin4–RING E3 ligase (CRL4) complex, capable of identifying C-terminal double-glutamic acid degrons to promote the degradation of specific substrates through the ubiquitin proteasome system. Melanoma-associated antigen 3 (MAGEA3) and T-complex protein 1 subunit epsilon (CCT5) proteins have been identified as cellular targets of DCAF12. To further characterize the interactions between DCAF12 and both MAGEA3 and CCT5, we developed a suite of biophysical and proximity-based cellular NanoBRET assays showing that the C-terminal degron peptides of both MAGEA3 and CCT5 form nanomolar affinity interactions with DCAF12 in vitro and in cells. Furthermore, we report here the 3.17 Å cryo-EM structure of DDB1–DCAF12–MAGEA3 complex revealing the key DCAF12 residues responsible for C-terminal degron recognition and binding. Our study provides new insights and tools to enable the discovery of small molecule handles targeting the WD40-repeat domain of DCAF12 for future proteolysis targeting chimera design and development.
Year:
2024
Protein arginine methyltransferase 9 (PRMT9) is a recently identified member of the PRMT family, yet its biological function remains largely unknown. Here, by characterizing an intellectual disability associated PRMT9 mutation (G189R) and establishing a Prmt9 conditional knockout (cKO) mouse model, we uncover an important function of PRMT9 in neuronal development. The G189R mutation abolishes PRMT9 methyltransferase activity and reduces its protein stability. Knockout of Prmt9 in hippocampal neurons causes alternative splicing of ~1900 genes, which likely accounts for the aberrant synapse development and impaired learning and memory in the Prmt9 cKO mice. Mechanistically, we discover a methylation-sensitive protein–RNA interaction between the arginine 508 (R508) of the splicing factor 3B subunit 2 (SF3B2), the site that is exclusively methylated by PRMT9, and the pre-mRNA anchoring site, a cis-regulatory element that is critical for RNA splicing. Additionally, using human and mouse cell lines, as well as an SF3B2 arginine methylation-deficient mouse model, we provide strong evidence that SF3B2 is the primary methylation substrate of PRMT9, thus highlighting the conserved function of the PRMT9/SF3B2 axis in regulating pre-mRNA splicing.
Year:
2024
The Pro/N-degron recognizing C-terminal to LisH (CTLH) complex is an E3 ligase of emerging interest in the developmental field and for targeted protein degradation (TPD) modalities. The human CTLH complex forms distinct supramolecular ring-shaped structures dependent on the multimerization of WDR26 or muskelin ß-propeller proteins. Here, we find that, in human cells, CTLH complex E3 ligase activity is dictated by a dynamic exchange between WDR26 and muskelin in tandem with muskelin autoregulation. Proteomic experiments revealed that complex-associated muskelin protein turnover is a major ubiquitin-mediated degradation event dependent on the CTLH complex in unstimulated HeLa cells. We observed that muskelin and WDR26 binding to the scaffold of the complex is interchangeable, indicative of the formation of separate WDR26 and muskelin complexes, which correlated with distinct proteomes in WDR26 and muskelin knockout cells. We found that mTOR inhibition-induced degradation of Pro/N-degron containing protein HMGCS1 is distinctly regulated by a muskelin-specific CTLH complex. Finally, we found that mTOR inhibition also activated muskelin degradation, likely as an autoregulatory feedback mechanism to regulate CTLH complex activity. Thus, rather than swapping substrate receptors, the CTLH E3 ligase complex controls substrate selectivity and its autoregulation through exchanging its β-propeller oligomeric subunits WDR26 and muskelin.
Year:
2024
Year:
2024
Collaborators (23)
Matthew Weitzman
Professor
Children's Hospital of Philadelphia
Masoud Vedadi
University of Toronto
Stuart Green
Staff Scientist
University of Toronto
Martin Haraldsson
Senior Scientist
Karolinska Institutet
Evert Homan
Karolinska Institutet
Matthieu Schapira
University of Toronto
Cheryl H. Arrowsmith
Chief Scientist
University of Toronto
Robert K. McGinty
Associate Professor
University of North Carolina at Chapel Hill
Stephen V. Frye
University of North Carolina at Chapel Hill
Lindsey I. James
University of North Carolina at Chapel Hill
Opher Gileadi
Head, Protein Sciences
Karolinska Institutet
Louisa Temme
Assistant Professor (Juniorprofessorin) of Pharmaceutical and Medicinal Chemistry
Universität Hamburg
Pengda Liu
Associate Professor
University of North Carolina at Chapel Hill
Caroline Schild-Poulter
Professor
Western University
Yi Xing
Professor
University of Pennsylvania
Matthew Todd
Chair of Drug Discovery
University College London
Eve Carter
University College London
Kenneth H. Pearce
Research Professor
University of North Carolina at Chapel Hill
Wenxin Felix Zhu
University of Münster
Melanie Uguen
University of North Carolina at Chapel Hill
Jacqueline Norris-Drouin
Senior Scientist
University of North Carolina
Taiping Chen
Professor
The University of Texas MD Anderson Cancer Center
Levon Halabelian
Assistant Professor
University of Toronto
Make your next move.
Prepare your application
Review drafts before you send them.